Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

June 15, 2018June 15, 2018

Data Supports Potential for Personalized Hemophilia A Therapy with Nuwiq, WFH Presentations Show

News

Since every hemophilia A patient responds differently to therapies, researchers are working to develop personalized preventive (prophylaxis) strategies with Nuwiq (antihemophilic factor .) Octapharma, the treatment’s manufacturer, presented data showing that ... Read more

June 13, 2018June 13, 2018

Hemophilia Patients Want to Lead More Active Lives, Survey Results Indicate

News

Preliminary results from the U.S. part of Bayer’s global HemACTIVE patient survey show that a majority of hemophilia patients want to be more active but are limited in their ... Read more

May 25, 2018May 25, 2018

Hemlibra Looks to Reach ‘Ultimate Goal’ of Treating All with Hemophilia A and with Choice in Dosing, Genentech Director Says

News

Should regulatory authorities agree with favorable results from Genentech’s ongoing Phase 3 studies of Hemlibra (emicizumab-kxwh), hemophilia A patients may have a treatment they can use regardless of inhibitor status, with ... Read more

May 23, 2018May 23, 2018

Hemlibra Ably Treats Hemophilia A Patients Regardless of Inhibitor Status, Data from 2 Phase 3 Trials Show

News

Data from ongoing Phase 3 clinical trials show that Genentech’s Hemlibra (emicizumab-kxwh) prophylaxis — or preventive treatment — greatly outperforms current standard-of-care therapies, leading to significant reductions in the ... Read more

May 16, 2018May 16, 2018

Valoctocogene Roxaparvovec Study Doses 1st Hemophilia Patient with Pre-existing AAV5 Antibodies

News

A Phase 1/2 trial (NCT03520712) testing BioMarin Pharmaceutical’s investigational gene therapy valoctocogene roxaparvovec in severe hemophilia A patients with pre-existing AAV5 antibodies has dosed its first participant. “Administration of valoctocogene ... Read more

May 11, 2018May 11, 2018

IV Self-Infusion Training Significantly Reduced Infections After Joint Replacement Surgery

News

Teaching hemophilia patients who have undergone joint replacement surgery how to administer their intravenous (IV) self-infusions in sterility, can decrease the rate of infections post-surgery significantly, a six-year education ... Read more

March 23, 2018March 23, 2018

Hemlibra is an Effective and Cost-saving Hemophila A Therapy, Report Finds

News

Hemlibra (emicizumab) is an effective and less costly therapy for hemophilia A patients who have substances in their blood that prevent clotting factor therapies from working as well as they ... Read more

February 21, 2018

Early Analysis Supports Eloctate Use in ITI Therapy for Severe Hemophilia A

News

Eloctate use in immune tolerance induction (ITI) therapy shows promise in high-risk patients with severe hemophilia A and inhibitors treated for the first time, Bioverativ announced. The results support a ... Read more

February 9, 2018February 9, 2018

Hemophilia B Bleeding-control Treatment Rebinyn Available in the United States

News

The hemophilia B treatment Rebinyn is available in the United States, its maker Novo Nordisk reports. Rebinyn, which is administered intravenously, replaces the blood clotting factor IX that is missing in ... Read more

January 15, 2018

uniQure Gene Therapy AMT-060 Shows Long-term Efficacy in Hemophilia B Patients

News

Gene therapy company uniQure released new data showing that its lead therapy AMT-060 for severe and moderately severe hemophilia B is safe and effective for up to two years, with adults requiring ... Read more

Pin It on Pinterest